Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: P2C 8443 Principal Investigator: Linette, Gerald
Title: Randomized Phase II Trial of Temozolomide versus Hyd-sulfate AZD6244 [NSC 748727] in Patients with Metastatic Uveal Melanoma
Phase: II Disease Site: Eye and Orbit
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this research study is to find out if treatment with AZD6244 or temozolomide
(TMZ) can stop your melanoma from growing. AZD6244 is an experimental drug. An experimental drug is a medication that is not approved by the FDA. AZD6244 is a pill that
blocks a protein called MEK. Most uveal melanomas grow because of MEK over-activity. This over-activity occurs because a protein called Gnaq or Gna11 is abnormal in the majority of uveal melanomas. Blocking MEK may shut down this pathway and stop your cancer from growing. Blocking MEK might work best in the tumors that have a mutation in Gnaq or Gna11.
 
More Information:
ClinicalTrials.gov #
Internal Protocol Documents (requires Siteman administrative database password)